Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A Plus Biotechnology Co's earnings per share without non-recurring items for the
three
months ended in Dec. 2025 was NT$1.11.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was NT$5.16.
During the past 12 months, A Plus Biotechnology Co's average earnings per share (NRI) Growth Rate was 3.70% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 51.10% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for A Plus Biotechnology Co's EPS without NRI or its related term are showing as below:
TPE:6918'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 9.7 Med: 51.1 Max: 64.1
Current: 51.1
During the past 7 years, A Plus Biotechnology Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 64.10% per year. The lowest was 9.70% per year. And the median was 51.10% per year.
TPE:6918's 3-Year EPS without NRI Growth Rate is ranked better than 89.29% of 663
companies
in the Medical Devices & Instruments industry
Industry Median: 8
vs TPE:6918: 51.10
A Plus Biotechnology Co (TPE:6918) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
A Plus Biotechnology Co EPS without NRI Related Terms
A Plus Biotechnology Co EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6918 vs ABT, SYK, MDT: EPS without NRI Comparison
For the Medical Devices subindustry, A Plus Biotechnology Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's PE Ratio without NRI falls into.
A Plus Biotechnology Co EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$5.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Plus Biotechnology Co (TPE:6918) has a EPS without NRI of NT$5.16 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on A Plus Biotechnology Co and its competitors. According to the industry distribution chart, A Plus Biotechnology Co ranks #71 out of 663 companies in the Medical Devices & Instruments industry, placing it in the top 10.7%.
Is A Plus Biotechnology Co's EPS without NRI too high?
A Plus Biotechnology Co's current EPS without NRI is NT$5.16. Based on the distribution chart, A Plus Biotechnology Co ranks #71 out of 663 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, A Plus Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's EPS without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #71 out of 663 companies for EPS without NRI. This places A Plus Biotechnology Co in the top 11% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 8.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.00, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current EPS without NRI is NT$5.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.29, compared to a current price of NT$72.80 — trading 16.6% below its estimated fair value. The current EPS without NRI is NT$5.16. A Plus Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current EPS without NRI is NT$5.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$72.80 is trading 16.6% below its estimated GF Value™ of NT$87.29.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
EPS without NRI: NT$5.16
GF Value™: NT$87.29 vs. price of NT$72.80 (16.6% below fair value)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
72GF Score
Get the complete analysis for TPE:6918
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
